News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC – Debyani Chakravarty
Photo taken from: Debyani Chakravarty / Twitter
Jul 17, 2023, 09:59

Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC – Debyani Chakravarty

My OncoKB people: Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC.

Looking fwd to it getting tumor agnostic approval based on Alison Schram work showing 42% ORR in PDAC (& 35% in NSCLC).

 

Source: Debyani Chakravarty / Twitter

FDA OncoDaily Oncology zenocutuzumab
Special Coverage
Science
Apr 1, 2025, 18:06
Toufic Kachaamy: A well-implemented FIT program can approach the long-term effectiveness of a one-time offer for a colonoscopy​
Blog
Apr 1, 2025, 17:49
Last post of the Trailblazers in Breast Cancer Research series - BCRF
Blog
Apr 1, 2025, 17:42
Sophia Hemsey: I had pleasure of partnering with St. Baldrick's Foundation for Alpha Kappa Psi's 5th annual Cocky and Bald event
Blog
Apr 1, 2025, 17:28
Ester Demirtshyan: Consider donating $10 to City of Smile to help children fighting cancer in Armenia
Blog
Apr 1, 2025, 17:18
Exploring AI’s Role in Cancer Care at ESTRO 2025
Blog
Apr 1, 2025, 17:01
The Power Over Cancer Gathering at Springhill Church - UF Health Cancer Center
Blog
Apr 1, 2025, 16:40
Estelamari Rodriguez: Speaking at the Latino Medical Student Association regional conference
Blog
Apr 1, 2025, 16:32
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers
Blog
Apr 1, 2025, 16:21
Azra Raza featured in SPCC's fifth episode of the "Behind Every Drug There’s a Story" series
Blog
Apr 1, 2025, 16:18
The EBMT 2025 Election Results
Career
Apr 1, 2025, 16:02
Jay Bhattacharya begins his tenure as the 18th NIH Director - National Institutes of Health
Positive
Apr 1, 2025, 15:45
Mark Lanasa: Positive CHMP opinion for BeOne Medicines' first-line immunotherapy in ES-SCLC